🔎 Under the Radar: Kodiak Stock Surges as Eye Drug Matches Regeneron’s
Kodiak Sciences' stock has surged up to 178% after its eye disease drugs, Zenkuda and tabirafusp-ted, matched Regeneron's Eylea in a phase 3 trial for wet age-related macular degeneration. The drugs met the primary endpoint of vision improvement at one year, with Zenkuda showing 7.2 letters improvement versus 7.6 for Eylea. Kodiak plans to seek approval of one of the candidates, potentially competing with Eylea and Vabysmo.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- âś“ Kodiak Sciences' stock surged up to 178% after positive phase 3 trial results.
- âś“ Zenkuda and tabirafusp-ted matched Eylea in vision improvement at one year in a phase 3 trial.
- âś“ Zenkuda showed 7.2 letters improvement versus 7.6 for Eylea in the trial.
- âś“ Kodiak plans to seek approval of one of the candidates, potentially competing with Eylea and Vabysmo.
What changed
Kodiak Sciences' stock surged after the company announced positive results from its phase 3 DAYBREAK trial, with both experimental drugs meeting the primary endpoint of vision improvement at one year.
Live updates
-
Kodiak Sciences Stock Surges as Eye Drug Matches Regeneron's Eylea
Kodiak Sciences' stock has surged up to 178% after its eye disease drugs, Zenkuda and tabirafusp-ted, matched Regeneron's Eylea in a phase 3 trial for wet age-related macular degeneration. The drugs met the primary endpoint of vision improvement at one year, with Zenkuda showing 7.2 letters improvement versus 7.6 for Eylea. Kodiak plans to seek approval of one of the candidates, potentially competing with Eylea and Vabysmo.
Why it matters
Kodiak Sciences' successful phase 3 trial results position the company as a significant competitor to Regeneron's blockbuster drug Eylea in the wet age-related macular degeneration market. The trial, called DAYBREAK, tested two experimental drugs: Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer (KSI-501).
What is confirmed
- Kodiak Sciences' stock surged up to 178% after positive phase 3 trial results.
- Zenkuda and tabirafusp-ted matched Eylea in vision improvement at one year in a phase 3 trial.
- Zenkuda showed 7.2 letters improvement versus 7.6 for Eylea in the trial.
- Kodiak plans to seek approval of one of the candidates, potentially competing with Eylea and Vabysmo.
- The phase 3 DAYBREAK trial tested two experimental drugs: Zenkuda and tabirafusp alfa tedromer (KSI-501).
What to watch next
- Kodiak Sciences' BLA filing for Zenkuda or tabirafusp-ted
- Regulatory approval and market launch of Kodiak's eye disease drugs
- Sales and market share performance of Kodiak's drugs compared to Eylea and Vabysmo
confidence 90%Sources used for this update (15)
- Forbes — Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
- Fierce Biotech — Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
- Yahoo Finance — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
- Investor's Business Daily — Why This Regeneron Eye Rival Just Catapulted More Than 120%
- WSJ — 🔎 Under the Radar: Kodiak Stock Surges as Eye Drug Matches Regeneron’s
- FirstWord — Kodiak surges on Phase III victory for Eylea rival in wet AMD
- finance.yahoo.com — Why Kodiak Sciences Skyrocketed Today
- www.fiercebiotech.com — Kodiak's stock doubles as resurrected eye disease drug ...
- www.biospace.com — Kodiak Sciences’ stock soars 166% after 2 assets ... - BioSpace
- finance.yahoo.com — Kodiak skyrockets on positive study data for 2 eye drugs
- finance.yahoo.com — Kodiak’s stock rallies on Phase III wAMD success
- www.talk.bio — Kodiak stock surges after two eye-drug candidates match Eylea ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community